Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QUCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Nasdaq formally notified company of minimum bid price violation; failure to cure by September 16, 2026 triggers delisting and potential debt defaults.
- Business Pivot (new) — Complete abandonment of biomedical business for speculative AI/quantum drone technology with zero operating history or proven revenue model.
- Dilution Overhang (new) — Outstanding preferred shares convertible into 477M ordinary shares represent 2,000%+ potential dilution versus current 22.8M share base.
Quantum Cyber pivots from biotech to AI/quantum drones, raises $15M amid Nasdaq delisting risk
Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Company abandoned biomedical diagnostics business entirely to pursue AI-powered autonomous vehicle control systems for drones, self-driving cars, and defense applications—a complete business transformation with no operating history.
Item 8.01 verify on EDGAR → -
high
Raised ~$15M from warrant exercises but disclosed 477M shares of potential dilution from preferred stock conversions—21x current 22.8M share count—creating massive overhang for existing holders.
Item 8.01 verify on EDGAR → -
high
Received Nasdaq deficiency notice for trading below $1.00 for 30 days; must regain compliance by September 16, 2026 or face delisting, which could trigger defaults on convertible notes and severely limit liquidity.
Item 8.01 verify on EDGAR → -
high
Management warns substantial additional capital will be needed for R&D, acquisitions, and commercialization of unproven quantum/AI technology, with no assurance funding will be available on acceptable terms.
Item 8.01 verify on EDGAR →
Summary
Quantum Cyber disclosed a dramatic corporate transformation, abandoning its biomedical diagnostics roots to chase AI-powered quantum computing applications for autonomous drones and defense systems.
While the company raised approximately $15 million through warrant exercises, the filing reveals existential risks: a Nasdaq delisting notice requiring share price recovery by mid-September, and a staggering 477 million shares of potential dilution from convertible preferred stock—more than 20 times the current outstanding share count.
The new business has zero operating history, and management explicitly warns that substantial additional capital will be required with no guarantee of availability. The company is essentially asking investors to bet on unproven quantum/AI technology while facing immediate delisting risk and massive dilution overhang. For existing shareholders, the warrant exercises provide temporary funding but at the cost of immediate dilution, while the preferred share conversions loom as a far larger threat. Watch the stock's bid price daily through September 16. If it fails to maintain $1.00 for 10 consecutive days before that deadline, delisting becomes likely, potentially triggering defaults on convertible debt and eliminating access to capital markets just as this cash-hungry pivot demands funding.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Quantum Cyber disclosed a business pivot from biotech to AI/quantum drone tech, warrant exercises raising ~$15M, and ongoing Nasdaq delisting risk.
Added in current filing · verify on EDGAR →
Quantum Cyber is a technology company focused on developing intelligent, scalable platforms that integrate artificial intelligence (“AI”) and quantum computing to power next-generation control systems for unmanned vehicles, aerial vehicles and underwater vehicles, such as drones, self-driving cars and robotic fleets.
The company disclosed a complete business pivot from biomedical diagnostics (PharmGenomics/Mainz Biomed) to AI-powered quantum drone technology. The 8-K describes the new business as developing autonomous vehicle control systems combining AI and quantum computing for defense, commercial logistics, and critical infrastructure. This represents a fundamental change in operations, target markets, and revenue model.
Added in current filing · verify on EDGAR →
On March 20, 2026, we received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of our ordinary shares for the 30 consecutive business days between February 5, 2026, to March 19, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a) (2). The letter also indicated that we will be provided with a compliance period of 180 calendar days, or until September 16, 2026, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c) (3) (A).
The company disclosed it received a Nasdaq deficiency notice for failing to maintain the $1.00 minimum bid price for 30 consecutive trading days. The company has until September 16, 2026 to regain compliance. If delisted, the filing warns of reduced liquidity, impaired ability to raise capital, and potential triggering of defaults under convertible notes.
Added in current filing · verify on EDGAR →
We also had outstanding, as of May 26, 2026, 1,000,000 Series A Preferred Shares, nominal value €0.01 per share, convertible into an aggregate of 9,000,000 ordinary shares, 1,000,000 Series B Preferred Shares, nominal value €0.01 per share, convertible into an aggregate of 9,000,000 ordinary shares, 1,000,000 Series C Preferred Shares, nominal value €0.01 per share, convertible into an aggregate of 9,000,000 ordinary shares, 1,000,000 Series D Preferred Shares, nominal value €0.01 per share, convertible into an aggregate of 225,000,000 ordinary shares, and 1,000,000 Series E Preferred Shares, nominal value €0.01 per share, convertible into an aggregate of 225,000,000 ordinary shares.
The company disclosed outstanding preferred shares convertible into up to 477 million ordinary shares (27 million from Series A/B/C and 450 million from Series D/E). With only 22.8 million ordinary shares currently outstanding, full conversion would represent approximately 21x dilution. This creates massive overhang and potential for severe shareholder dilution.
Added in current filing · verify on EDGAR →
The Company’s current business strategy involving AI-enabled autonomous systems, drone technologies, cybersecurity applications, quantum optimization technologies, and defense-related operational systems is relatively new and evolving. As a result, investors have limited historical information upon which to evaluate the Company’s business prospects, operational capabilities, or likelihood of achieving commercial success.
The company explicitly disclosed it has a limited operating history in its new AI/quantum drone business and warned that substantial additional capital will be required to fund R&D, acquisitions, commercialization, and operations. The filing states additional financing may not be available on acceptable terms or at all, and future equity financing could be dilutive while debt could impose restrictive covenants.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify